A Review of Autologous Stem Cell Transplantation in Lymphoma

Overview

Journal Curr Hematol Malig Rep

Publisher Current Science

Specialties Hematology
Oncology

Date 2017 May 8

PMID 28478586

Citations 39

Authors

Umar Zahid

Faisal Akbar

Akshay Amaraneni

Muhammad Husnain

Onyee Chan

Irbaz Bin Riaz

Ali McBride

Ahmad Iftikhar

Faiz Anwer

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Chemotherapy remains the first-line therapy for aggressive lymphomas. However, 20-30% of patients with non-Hodgkin lymphoma (NHL) and 15% with Hodgkin lymphoma (HL) recur after initial therapy. We want to explore the role of high-dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) for these patients.

Recent Findings: There is some utility of upfront consolidation for-high risk/high-grade B-cell lymphoma, mantle cell lymphoma, and T-cell lymphoma, but there is no role of similar intervention for HL. New conditioning regimens are being investigated which have demonstrated an improved safety profile without compromising the myeloablative efficiency for relapsed or refractory HL. Salvage chemotherapy followed by HDT and rescue autologous stem cell transplant remains the standard of care for relapsed/refractory lymphoma. The role of novel agents to improve disease-related parameters remains to be elucidated in frontline induction, disease salvage, and high-dose consolidation or in the maintenance setting.

Citing Articles

What We Know and Do Not Yet Know About the Canine Model of Lymphoma in Human Medicine-The Current State of Knowledge.

Bedkowska D, Al-Ameri S, Wieczorek A, Bubak J, Miszczak M Cancers (Basel). 2025; 17(4).

PMID: 40002191 PMC: 11853190. DOI: 10.3390/cancers17040596.

Prognostic factors and treatment outcomes of allogeneic stem cell transplantation in lymphoid malignancy.

Kim H, Chung H, Kook H, Kim S, Kim Y, Cho H Blood Res. 2025; 60(1):12.

PMID: 39928273 PMC: 11811309. DOI: 10.1007/s44313-025-00060-y.

Primary Sacral Activated B-Cell Like Diffuse Large B-Cell Lymphoma, Triple Expressor Type: A Case Report with Literature Review.

Mohapatra D, Tripathy P, Mohanty S, Pal A J Microsc Ultrastruct. 2025; 12(4):228-231.

PMID: 39811597 PMC: 11729018. DOI: 10.4103/jmau.jmau_64_22.

Mitoxantrone-Based Novel Conditioning Regimen Leads to Great Survival Benefit in Peripheral T-Cell Lymphoma Compared to BEAM Regimen.

Zuo X, Qian W, Wu M, Xie Y, Ma J Cancer Med. 2024; 13(23):e70476.

PMID: 39651710 PMC: 11626477. DOI: 10.1002/cam4.70476.

Sex-Based Differences in Risk of Therapy-Related Myeloid Neoplasms.

Richard M, Yan C, Chen Y, Gibson C, Kalra R, Bosworth A J Clin Oncol. 2024; 42(31):3739-3750.

PMID: 39094067 PMC: 11521772. DOI: 10.1200/JCO-24-01487.

References

Ramzi M, Mohamadian M, Vojdani R, Dehghani M, Nourani H, Zakerinia M . Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. Exp Clin Transplant. 2012; 10(2):163-7. DOI: 10.6002/ect.2011.0092. View

Auger-Quittet S, Duny Y, Daures J, Quittet P . Outcomes after (90) Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis. Cancer Med. 2014; 3(4):927-38. PMC: 4303160. DOI: 10.1002/cam4.247. View

Malik S, Liu K, Qiang X, Sridhara R, Tang S, McGuinn Jr W . Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2010; 16(20):4921-7. DOI: 10.1158/1078-0432.CCR-10-1214. View

Parovichnikova E, Kuzmina L, Mendeleeva L, Klyasova G, Troitskaya V, Sokolov A . [Autologous hematopoietic stem cell transplantation as late high-dose consolidation in adult patients with T-cell lymphoblastic leukemias: Results of a Russian multicenter study]. Ter Arkh. 2015; 87(7):15-25. DOI: 10.17116/terarkh201587715-25. View

Yun S, Vincelette N, Abraham I, Puvvada S, Anwer F . Outcome Comparison of Allogeneic versus Autologous Stem Cell Transplantation in Transformed Low-Grade Lymphoid Malignancies: A Systematic Review and Pooled Analysis of Comparative Studies. Acta Haematol. 2016; 136(4):244-255. DOI: 10.1159/000449031. View

Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch D, Trneny M . Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28(27):4184-90. PMC: 3664033. DOI: 10.1200/JCO.2010.28.1618. View

Arai S, Letsinger R, Wong R, Johnston L, Laport G, Lowsky R . Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma. Biol Blood Marrow Transplant. 2010; 16(8):1145-54. PMC: 2921221. DOI: 10.1016/j.bbmt.2010.02.022. View

Taverna J, Yun S, Jonnadula J, Saleh A, Riaz I, Abraham I . Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas: A Systematic Review. Biol Blood Marrow Transplant. 2016; 22(7):1182-1196. DOI: 10.1016/j.bbmt.2016.02.007. View

Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho A, Metzner B . Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010; 116(18):3418-25. DOI: 10.1182/blood-2010-02-270785. View

10.

Dearden C, Johnson R, Pettengell R, Devereux S, Cwynarski K, Whittaker S . Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol. 2011; 153(4):451-85. DOI: 10.1111/j.1365-2141.2011.08651.x. View

11.

Younes A, Santoro A, Shipp M, Zinzani P, Timmerman J, Ansell S . Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016; 17(9):1283-94. PMC: 5541855. DOI: 10.1016/S1470-2045(16)30167-X. View

12.

DAmore F, Relander T, Lauritzsen G, Jantunen E, Hagberg H, Anderson H . Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012; 30(25):3093-9. DOI: 10.1200/JCO.2011.40.2719. View

13.

Karlin L, Coiffier B . The changing landscape of peripheral T-cell lymphoma in the era of novel therapies. Semin Hematol. 2014; 51(1):25-34. DOI: 10.1053/j.seminhematol.2013.11.001. View

14.

Falzetti F, Di Ianni M, Ballanti S, Iodice G, Reale A, Minelli O . High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma. Clin Exp Med. 2011; 12(3):165-71. DOI: 10.1007/s10238-011-0157-2. View

15.

Linch D, Winfield D, Goldstone A, Moir D, Hancock B, McMillan A . Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993; 341(8852):1051-4. DOI: 10.1016/0140-6736(93)92411-l. View

16.

Schorb E, Finke J, Ferreri A, Ihorst G, Mikesch K, Kasenda B . High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix). BMC Cancer. 2016; 16:282. PMC: 4839072. DOI: 10.1186/s12885-016-2311-4. View

17.

Ellin F, Landstrom J, Jerkeman M, Relander T . Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014; 124(10):1570-7. DOI: 10.1182/blood-2014-04-573089. View

18.

Beitinjaneh A, Saliba R, Medeiros L, Turturro F, Rondon G, Korbling M . Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. Biol Blood Marrow Transplant. 2015; 21(5):855-9. PMC: 4408269. DOI: 10.1016/j.bbmt.2015.01.013. View

19.

Sonnen R, Schmidt W, Muller-Hermelink H, Schmitz N . The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol. 2005; 129(3):366-72. DOI: 10.1111/j.1365-2141.2005.05478.x. View

20.

von Tresckow B, Moskowitz C . Treatment of relapsed and refractory Hodgkin Lymphoma. Semin Hematol. 2016; 53(3):180-5. PMC: 5637390. DOI: 10.1053/j.seminhematol.2016.05.010. View